Treatment Practice and Analysis under the Collaboration between Doctors and Pharmacists in Patient with Diffuse Large B-Cell Lymphoma Complicated by Severe Renal Insufficiency

Background The main treatment for diffuse large B-cell lymphoma is immunochemotherapy. However, the transport of most chemotherapy drugs in the body relies on the participation of the kidneys. For patients with diffuse large B-cell lymphoma, the coexistence of severe renal insufficiency undoubtedly poses a significant challenge to treatment. During the treatment process, doctors and pharmacists need to closely cooperate to maximize the therapeutic benefits for patients while ensuring their safety. Objective To explore the treatment service model for patients with diffuse large B-cell lymphoma complicated by acute renal failure, so as to establish effective preventive and treatment measures. Methods Taking the clinical data of a patient with diffuse large B-cell lymphoma complicated with severe renal insufficiency who received polatuzumab vedotin combined with chemotherapy as an example. Explore the etiology, prognostic assessment, treatment feasibility, risk assessment and management of tumor lysis syndrome, adjustment of treatment regimens, key points of pharmaceutical care analysis and determination of dialysis timing, etc. Results The patient's treatment process was stable, and no tumor lysis syndrome occurred. After 2 cycles of treatment, the symptoms of tumor compression were relieved, acute renal failure was effectively alleviated, and the lactate dehydrogenase level tended to be normal. Conclusion There are significant individual differences among patients with diffuse large B-cell lymphoma complicated by renal failure. The clinical treatment regimens should be individualized based on clear examinations and comprehensive assessments. Doctors and pharmacists should strengthen communication to ensure the safety and effectiveness of treatment.